<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642847</url>
  </required_header>
  <id_info>
    <org_study_id>B7471005</org_study_id>
    <nct_id>NCT03642847</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age</brief_title>
  <official_title>A PHASE 1B, RANDOMIZED, CONTROLLED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY JAPANESE ADULTS 18 TO 49 YEARS OF AGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b will describe the safety and immunogenicity of 2 multivalent pneumococcal
      conjugate vaccine formulations in healthy Japanese adults in the United States.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects reporting prompted local reactions within 14 days after vaccination (redness, swelling, and pain at the injection site).</measure>
    <time_frame>14 days after vaccination</time_frame>
    <description>Subjects reporting prompted local reactions within 14 days after vaccination (redness, swelling, and pain at the injection site).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects reporting prompted systemic events within 14 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain).</measure>
    <time_frame>14 days after vaccination</time_frame>
    <description>Subjects reporting prompted systemic events within 14 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects reporting adverse events (AEs) within 1 month after vaccination.</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Subjects reporting adverse events (AEs) within 1 month after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects reporting serious adverse events (SAEs) within 6 months after vaccination.</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>Subjects reporting serious adverse events (SAEs) within 6 months after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects reporting newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination.</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>Subjects reporting newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Pneumococcal serotype-specific OPA titers 1 month after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Prevnar 13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13 valent Pneumococcal Conjugate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multivalent pneumococcal conjugate formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multivalent pneumococcal conjugate formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multivalent pneumococcal conjugate formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multivalent pneumococcal conjugate formulation 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13</intervention_name>
    <description>13 valent Pneumococcal Conjugate</description>
    <arm_group_label>Prevnar 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>multivalent pneumococcal conjugate formulation 1</intervention_name>
    <description>multivalent pneumococcal conjugate formulation 1</description>
    <arm_group_label>multivalent pneumococcal conjugate formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>multivalent pneumococcal conjugate formulation 2</intervention_name>
    <description>multivalent pneumococcal conjugate formulation 2</description>
    <arm_group_label>multivalent pneumococcal conjugate formulation 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Japanese subjects 18 to 49 years of age, defined as Japanese born in
             Japan, with both parents and 4 grandparents who wer born in Japan (family tree by
             history), and who have not lived outside of Japan for more than 5 years total
             (confirmed by passport or interview)

        Exclusion Criteria:

          -  Participation in other studies involving investigational drug(s), investigational
             vaccines, or investigational medical devised within 28 days prior to study entry
             and/or during study participation. Participation in purely observational studies is
             acceptable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7471005&amp;StudyName=A+PHASE+1B%2C+RANDOMIZED%2C+CONTROLLED%2C+DOUBLE-BLIND+TRIAL+TO+EVALUATE+THE+SAFETY+AND+IMMUNOGENICITY+OF+MULTIVALENT+PNEUMOCOCCAL+CONJUGATE+VACCINES+IN+HEALTHY+JAPANESE+ADULTS+18+TO+49+YEARS+OF+AGE</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

